Authored by James Sheppard
The Oslo biotech cluster based Vaccibody announced that it had successfully completed a 35m NOK (US $6m) financing round. The money has been raised via the public market in Norway by issuing new shares with new and existing investors coming on board.
Vaccibody is a cancer-immunotherapy company developing vaccines for cancer, human infectious diseases and veterinary infectious diseases. The company’s lead asset is VB1016 which is a DNA based immunotherapy targeting malignancies caused by Human Papilloma Virus 16 (HPV16). HPV16 is a major contributor to several cancers, including Cervical, Vulvar, Anal and Head and Neck Cancer. Vaccibody is currently preparing the initiation of its first proof of concept study in patients with HPV16 induced pre-malignancies of the Cervix (Cervical Intraepithelial Neoplasia).
The funding round saw Datum and Partners join existing investors Artic Securities and Norwegian Cancer Society. The money raised from this funding round will be used to initiate the company’s first clinical study for VB1016.